Clik here to view.
Isotechnika and 3SBio ink licence deal
Isotechnika Pharma (TSX:ISA) and 3SBio, Inc., a Chinese biotechnology company, have signed a development and commercialization agreement for Isotechnika’s voclosporin drug to prevent organ rejection...
View ArticleClik here to view.
Isotechnika licenses voclosporin to ILJIN Life
Isotechnika Pharma (TSX:ISA) has entered into a development, distribution and licence agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, for the further clinical and...
View ArticleClik here to view.
Donald Wyatt joins Isotechnika board
Donald Wyatt, the founder of consultancy The Wyatt Group, has been appointed a director of Isotechnika Pharma (TSX:ISA), serving as a representative of 3SBio (NASDAQ:SSRX), a Chinese biotech company....
View ArticleClik here to view.
Isotechnika partner cleared for Phase 3 trial in China
Isotechnika’s voclosporin is a potential breakthrough drug to prevent rejection of a transplanted kidney Isotechnika Pharma (TSX:ISA) partner 3SBio (NASDAQ:SSRX) has received approval from the China’s...
View ArticleClik here to view.
Glickman swinging for the fence again in Isotechnika merger
Richard Glickman is poised to hit another home run with the proposed merger of his closely-held Aurinia Pharmaceuticals and Isotechnika Pharma (TSX:ISA) to create a global nephrology leader. Richard...
View Article
